报价延迟最少15分钟:2026/03/05 14:15 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.5 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.56/-0.97
|
|
企业价值
55.55M
|
| 资产负债 |
|
每股账面净值
11.94
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
636.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders. |
